Thursday, May 17, 2012

889- Marine Patent prosecution update


Read, understand and consent to the blog's DISCLAIMER here before proceeding to read the article


Lavin declaration - This is evidence that none of the patients in the katayama study had TG>=500
 http://www.scribd.com/doc/93949103/Lavin-declaration
Applicant's arguments (read page 7 on interview summary with the examiner's supervisor) http://www.scribd.com/doc/93949302/Marine-patent-applicant-arguments
Dr. Reddy's v Astrazeneca (case law towards "claimed lipid parameters should be accorded patentable weight") 
http://www.scribd.com/share/upload/88664989/lxiegksa9tbtga5ss01
Amended Claims
http://www.scribd.com/doc/93950085/amended-claims-marine
Composition of matter

Their 598 COM patent IMO is somewhat weak. It is good to prevent generics but maybe not so good to prevent slightly changed copycats(of course the copycats may have to run clinical trials). I like the main claim(s) in this new patent app. "A pharmaceutical composition comprising EPA and a cardiovascular agent, wherein the composition contains not more than 10% DHA by weight, if any."
Link

No comments:

Post a Comment